Company Encyclopedia
View More
name
Kontour Medical
688314.SH
Kontour (Xi'an) Medical Technology Co., Ltd. engages in the research and development, production, and sale of Class III implantable medical devices in China. The company offers products in the fields of neurosurgery cranial repair and fixation, cardiothoracic surgery sternum fixation, maxillofacial repair, and stomatology. It also provides oral products, including implants, implant guides, titanium mesh, GBR series nails, dental tool boxes, and related surgical auxiliary instruments.
883.73 B
688314.SHMarket value -Rank by Market Cap -/-

Financial Score

22/11/2025 Update
B
Health Care EquipmentIndustry
Industry Ranking25/63
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreA
    • ROE13.33%B
    • Profit Margin26.55%A
    • Gross Margin79.63%A
  • Growth ScoreB
    • Revenue YoY7.90%B
    • Net Profit YoY0.60%C
    • Total Assets YoY7.22%B
    • Net Assets YoY7.74%B
  • Cash ScoreC
    • Cash Flow Margin376.60%C
    • OCF YoY7.90%B
  • Operating ScoreC
    • Turnover0.44C
  • Debt ScoreA
    • Gearing Ratio12.72%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Kontour Medical released its performance for the first three quarters, with a net profit attributable to the parent company of 76.72 million yuan, remaining flat year-on-year

    According to the Zhitong Finance APP, Kontour Medical disclosed its third-quarter report for 2025. The company achieved revenue of 251 million yuan in the first three quarters, a year-on-year increase of 4.57%; net profit attributable to the parent company was 76.72 million yuan, unchanged year-on-year; net profit excluding non-recurring items was 71.61 million yuan, a year-on-year increase of 7.80%; basic earnings per share were 0.94 yuan

    Zhitong·
    SH
    688314
    -4.72%
    Zhitong·
    SH
    688314
    -4.72%

    Kontour Medical released its semi-annual performance, with a net profit attributable to the parent company of 54.9986 million yuan, a year-on-year increase of 12.72%

    According to the Zhitong Finance APP, Kontour Medical disclosed its semi-annual report for 2025. During the reporting period, the company achieved revenue of 170 million yuan, a year-on-year increase of 11.07%; net profit attributable to shareholders was 54.9986 million yuan, a year-on-year increase of 12.72%; net profit excluding non-recurring items was 50.3874 million yuan, a year-on-year increase of 25.02%; basic earnings per share were 0.68 yuan. The company plans to distribute a cash dividend of 2 yuan (including tax) for every 10 shares to all shareholders

    Zhitong·
    SH
    688314
    -4.72%
    Zhitong·
    SH
    688314
    -4.72%

    Kontour Medical: Net profit of 24.0482 million yuan in the first quarter of 2025, a year-on-year increase of 20.63%

    Kontour Medical announced that its revenue for the first quarter of 2025 was 82.491 million yuan, a year-on-year increase of 17.98%; net profit was 24.0482 million yuan, a year-on-year increase of 20.63%

    Zhitong·
    SH
    688314
    -4.72%
    Zhitong·
    SH
    688314
    -4.72%

    Kontour Medical released its 2024 annual performance, with a net profit attributable to the parent company of 88.4 million yuan, a year-on-year increase of 17.07%

    Kontour Medical released its 2024 annual performance, achieving revenue of 322 million yuan during the reporting period, a year-on-year increase of 17.06%; the net profit attributable to shareholders was 88.4 million yuan, a year-on-year increase of 17.07%. The company plans to distribute a cash dividend of 1.8 yuan for every 10 shares to all shareholders. The core products in neurosurgery performed outstandingly, with total revenue from PEEK materials and titanium materials reaching 278.0188 million yuan, accounting for 89.19% of the main business income. The company continues to optimize its products through technological innovation, consolidating its leading position in the field of neurosurgical repair and fixation

    Zhitong·
    SH
    688314
    -4.72%
    Zhitong·
    SH
    688314
    -4.72%

    Kontour Medical's net profit in 2024 is 88.5708 million yuan, an increase of 17.3%

    Kontour Medical released its 2024 performance preliminary report, with operating revenue reaching 322 million yuan, a year-on-year increase of 17.06%; net profit was 88.5708 million yuan, a year-on-year increase of 17.30%. The net profit after deducting non-recurring gains and losses was 75.0325 million yuan, an increase of 9.77%. The basic earnings per share were 1.09 yuan. The company expects that as the centralized procurement in neurosurgery progresses, the growth rate of net profit will remain consistent with the growth rate of revenue

    Zhitong·
    SH
    688314
    -4.72%
    Zhitong·
    SH
    688314
    -4.72%